| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S18387 R77531 |
Heuvelman - Venlafaxine, 2023 | Attention deficit hyperactivity disorder -Medical codes or therapy records that indicated that the child had been prescribed ADHD medication - Mean age at end of follow-up 10.04 years, range 4–22 years | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed, sick | Adjustment: Yes Monotherapy: no or not specified Unexposed sick: intermediate history of illness/treatment (3-12 months before pregnancy) | 0.97 [0.48;1.96] | -/818 -/16,330 | - | 818 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S18333 R77346 |
Suarez - SNRI (Controls unexposed, discontinuers), 2022 | Attention Deficit Hyperactivity Disorder - ≥ 2 dates with ICD-9 Dx 314.xx or ≥ 2 dispensings or 1 diagnosis and 1 dispensing - At ≥ 2 years of age | 2nd and/or 3rd trimester | retrospective cohort (claims database) | unexposed, sick | Adjustment: Yes Monotherapy: no or not specified Unexposed sick: recent illness/treatment (during or juste before pregnancy or treatment stopped in view of pregnancy) | 0.80 [0.61;1.04] | 256/8,540 171/4,899 | 427 | 8,540 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S18334 R77357 |
Suarez - SNRI (Controls unexposed, general pop), 2022 | Attention Deficit Hyperactivity Disorder - ≥ 2 dates with ICD-9 Dx 314.xx or ≥ 2 dispensings or 1 diagnosis and 1 dispensing - At ≥ 2 years of age | 2nd and/or 3rd trimester | retrospective cohort (claims database) | unexposed (general population or NOS) excluded | Adjustment: Yes Monotherapy: no or not specified |
1.07 [0.94;1.23] excluded (control group) |
258/8,659 51,087/2,910,114 | 51,345 | 8,659 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S12487 R47104 |
Yeh - SNRI, 2021 | Attention-deficit/hyperactivity disorder (ADHD - at least twice outpatient visits within each year for ICD-9 code: 314) - At 0-10 years old | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed, sick | Adjustment: Yes Monotherapy: no or not specified Unexposed sick: old history of illness/treatment (> 12 months before pregnancy) or not specified | 2.53 [1.26;5.06] | -/56 -/5,243 | - | 56 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S11704 R46833 |
Boukhris - SNRI (Controls exposed to TCA) , 2017 | Infants with attention deficit hyperactivity disorder (ADHD-ICD9: 314.0; 314.01; 314.9; ICD10:F90;F90.0;F90.1;F90.2; F90.8;F90.9 or ADHD medications) - Mean 6-7 years old (0-11 years) | 2nd and/or 3rd trimester | retrospective cohort (claims database) | exposed to other treatment, sick excluded | Adjustment: No Monotherapy: SNRI only |
0.56 [0.28;1.11] C excluded (control group) |
18/445 16/227 | 34 | 445 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S11705 R46834 |
Boukhris - SNRI (Controls unexposed, NOS), 2017 | Infants with attention deficit hyperactivity disorder (ADHD-ICD9: 314.0; 314.01; 314.9; ICD10:F90;F90.0;F90.1;F90.2; F90.8;F90.9 or ADHD medications) - Mean 6-7 years old (0-11 years) | 2nd and/or 3rd trimester | retrospective cohort (claims database) | unexposed (general population or NOS) | Adjustment: Yes Monotherapy: SNRI only | 1.40 [0.80;2.50] | 18/445 4,430/141,905 | 4,448 | 445 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S11706 R46835 |
Laugesen - SNRI, 2013 | Attention deficit hyperactivity disorder ADHD (diagnosis of ADHD or a redemption of a prescription for ADHD medication) - Median 8 years old (1-14 years) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed (general population or NOS) | Adjustment: Yes Monotherapy: SNRI only | 1.00 [0.40;2.50] | -/763 -/816,792 | - | 763 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 5 studies | 1.18 [0.77;1.81] | 4,875 | 10,622 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Controls unexposed, discontinuers; 2: Controls unexposed, NOS;
Asymetry test p-value = 0.2084 (by Egger's regression)
slope=-0.4892 (0.3353); intercept=2.2233 (1.3916); t=1.5976; p=0.2084
excluded 11704, 18334